1 pahu (10 Vials)
| Loaʻa: | |
|---|---|
| Ka nui: | |
▎ He aha ka Ipamorelin?
ʻO Ipamorelin kahi pūhui pentapeptide synthetic no ka ʻohana secretagogue hormone ulu. ʻO kāna hana koʻikoʻi ka hoʻoulu ikaika ʻana i ka hoʻokuʻu ʻana o ka hormone ulu a hoʻoikaika i ka synthesis o ka insulin-like growth factor-1 (IGF-1), a laila e pāʻani ana i kahi kuleana i ka hoʻoponopono ʻana i ka metabolism, hoʻoikaika i ka hoʻoponopono ʻana o ka ʻiʻo, a me ke kākoʻo ʻana i ka ulu. Ua hōʻike ʻia nā haʻawina lāʻau lapaʻau e hiki iā Ipamorelin ke hoʻolalelale i ka ʻōpū o ka ʻōpū, hoʻomaikaʻi i nā hōʻailona o ka postoperative ileus, a hoʻēmi i ka ʻeha visceral a me ka somatic non-inflammatory ma o ka hoʻoponopono ʻana i nā kaʻina hana physiological pili. Ke hoʻohālikelike ʻia me nā secretagogues hormone ulu kahiko, hōʻike ʻo Ipamorelin i ke koho kiʻekiʻe no ka hoʻokuʻu ʻana o ka hormone ulu a ʻaʻole pili nui i ka huna ʻana o nā hormones ʻē aʻe (e like me ka hormone adrenocorticotropic a me cortisol). Hāʻawi kēia mau pōmaikaʻi kūʻokoʻa iā ia me nā noi kūpono i ka mālama ʻana i ka hemahema o ka hormone ulu, nā maʻi motility gastrointestinal, a me ka mālama ʻana i ka ʻeha.
▎ Ipamorelin Structure
Puna: PubChem |
Kaʻina: XHXFK Hui Molekala: C 38H 49N 9O5 Kaumaha Molekala: 711.9 g/mol Helu CAS: 170851-70-4 PubChem CID: 9831659 Synonyms: NNC-26-0161;UNII-Y9M3S784Z6;IPAMORELIN ACETATE |
▎ Ipamorelin Research
He aha ke kumu noiʻi o Ipamorelin?
He ʻano maʻamau ka lohi ʻana o ka ʻōpū o ka ʻōpū, a i kēia manawa, liʻiliʻi nā koho lapaʻau kūpono. Ua ʻike ʻia ka noiʻi ʻana ʻo Ipamorelin, ma ke ʻano he peptidomimetic synthetic, ke hana nei i ka ghrelin receptor a loaʻa paha kahi hopena therapeutic i ka lohi ʻana o ka ʻōpū. Ma kahi noiʻi e pili ana i kahi ʻano koʻikoʻi o ka gastroparesis, ua hoʻoulu ʻia ka gastroparesis e ka ʻoki ʻōpū a me ka hoʻoponopono ʻana i ka ʻōpū, a ua ʻike ʻia ua hiki iā Ipamorelin ke hoʻolalelale i ka ʻōpū o ka ʻōpū [1].
He paʻakikī koʻikoʻi ka ileus postoperative i ka hana lapaʻau, nele i nā hoʻolālā hoʻokele kūpono. ʻO ka hoʻoulu ʻana o ka mea hoʻokipa Ghrelin he hopena hoʻoikaika motility ma nā ʻaoʻao o luna a me lalo o ka ʻōpū o ka ʻōpū. Ma ke ʻano he ghrelin receptor agonist, loaʻa iā Ipamorelin ka waiwai hoʻohana pono i ka mālama ʻana i ka ileus postoperative. No ka laʻana, i loko o kahi noiʻi, ua mālama ʻia kahi haʻawina hoʻopaʻa ʻia, randomized, controlled proof-of-concept study i nā poʻe maʻi e hoʻopau ana i ka ʻōpū ma hope o ka ʻoki ʻana i ka ʻōpū e loiloi i ka palekana a me ka pono o Ipamorelin [2].
No ka Ipamorelin ka hormone hoʻokuʻu i nā peptides (GHRPs), he pentapeptide synthetic hiki ke hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu mai ka hypothalamus a me ka pituitary gland. He mea koʻikoʻi ka hormone ulu i ka ulu ʻana o ke kino, hoʻoponopono, a me ka metabolism, no laila, ʻo ke kuleana o Ipamorelin i ka hoʻoponopono ʻana i ka hormone ulu ua hoʻokipa nui ʻia [3].
Ma muli o kona waiwai kūpono i ka mālama ʻana i ka hoʻokuʻu ʻana o ka ʻōpū, postoperative ileus, a me kāna kuleana ma ke ʻano he hormone ulu e hoʻokuʻu ana i ka peptide, ua huki ʻo Ipamorelin i ka nānā noiʻi nui.
He aha ke ʻano o ka hana a Ipamorelin?
1. Hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu:
Aia ka Ipamorelin i ka hormone ulu e hoʻokuʻu ana i nā peptides (GHRPs), hiki ke hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu mai ka hypothalamus a me ka pituitary gland. ʻO nā hoʻokolohua in vitro a me in vivo, ua hōʻike ʻo Ipamorelin i ka mana kiʻekiʻe a me ka pono i ka hoʻokuʻu ʻana i ka hormone ulu. Eia kekahi laʻana, i loko o kahi noiʻi, ua like ka mana a me ka pono o Ipamorelin i ka hoʻokuʻuʻana i ka hormone ulu mai nā pūnaewele pituitary rat mua me ka GHRP-6 [3] . ʻO kāna hana o ka hana e hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu ma o ka hoʻoulu ʻana i nā mea loaʻa like GHRP. Ma o ka pharmacological analysis, ua hōʻoia ʻia e like me GHRP-6, hoʻoulu ʻo Ipamorelin i ka hoʻokuʻu ʻana o ka hormone ulu ma o nā mea loaʻa like GHRP.
2. Nā hopena ma ka ʻōpū o ka ʻōpū
ʻO ka hoʻomaʻemaʻe ʻana i ka ʻōpū:
I nā hoʻohālike rodent, hiki iā Ipamorelin ke hoʻolalelale i ka hemo ʻana o ka ʻōpū. Hoʻopaneʻe ka ʻoki ʻana i ka ʻōpū, akā ma hope o ka hoʻohana ʻana iā Ipamorelin (0.014 µmol/kg intravenously), ʻoi aku ka wikiwiki o ka hemo ʻana o ka ʻōpū. Hoʻoulu ʻo Ipamorelin i ka contractility gastric a hoʻolalelale i ka hoʻokaʻawale ʻana o ka ʻōpū ma o kahi mīkini i hoʻopili ʻia e ka hoʻāla ʻana o ka ghrelin receptor, e pili ana i nā neurons excitatory cholinergic (Greenwood-Van Meerveld B, 2012).
Hoʻomaikaʻi i nā hōʻailona o ka ileus postoperative:
I nā hiʻohiʻona rodent o postoperative ileus, hiki iā Ipamorelin ke hoʻomaikaʻi i nā hōʻailona. Ma hope o ka lawelawe ʻana o Ipamorelin ma hope o ka hana ʻana, hiki i kahi ʻāpana o Ipamorelin (1mg / kg) a i ʻole GHRP-6 (20μg / kg) ke hoʻemi i ka manawa i ka defecation mua. ʻO ka hoʻohana hou ʻana o Ipamorelin (0.1 a i ʻole 1mg / kg) hiki ke hoʻonui nui i ka puka fecal cumulative, ʻai meaʻai, a me ke kaumaha [4].
3. Nā hopena i ka huna ʻana o ka insulin
Hiki i ka Ipamorelin ke hoʻoulu i ka huna ʻana o ka insulin i nā ʻāpana kiko pancreatic o nā ʻiole maʻamau a me ka maʻi diabetes. ʻO ka hoʻonui ʻana i ka huna ʻana o ka insulin i hoʻokomo ʻia e Ipamorelin hiki ke kāohi nui ʻia e ka diltiazem, yohimbine, propranolol, a i ʻole ka hui pū ʻana o ka atropine, propranolol, a me yohimbine. I nā ʻiole diabetic, hiki i ka atropine ke hoʻemi nui i ka huna ʻana o ka insulin i hoʻoiho ʻia e Ipamorelin, akā ʻaʻole ʻike ʻia kēia hopena i nā ʻiole maʻamau. Hōʻike kēia i ka hoʻoulu ʻana o Ipamorelin i ka hoʻokuʻu ʻana o ka insulin ma o ke kahawai calcium a me nā alaloa adrenergic receptor [5].
4. Hoʻopau i ka ʻeha
I nā ʻano hoʻokolohua o ka hypersensitivity visceral non-inflammatory a me somatic mechanical allodynia, ʻo Ipamorelin, ma ke ʻano he agonist receptor ghrelin i kaupalena ʻia, hiki ke hoʻemi nui i ka hypersensitivity colonic a me somatic allodynia. Hoʻopili ʻia kāna ʻano hana e ka ghrelin receptor, a hiki ke kāohi ʻia kēia hopena antinociceptive e ka ghrelin receptor antagonist H0900 [6].

Pehea ka hopena o ipamorelin i ka huna ʻana o ka insulin mai nā ʻāpana ʻiʻo pancreatic o nā ʻiole maʻamau a me ka maʻi diabetes.
Puna:PubMed [5]
He aha nā mea hoʻohana o Ipamorelin?
1. Hoʻolaha i ka hoʻokuʻu ʻana o ka hormone ulu
Hiki i ka Ipamorelin ke hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu mai ka hypothalamus a me ka pituitary gland. He mea koʻikoʻi ka hormone ulu i ke kino o ke kanaka, me ka hoʻoikaika ʻana i ka synthesis protein, ka hoʻonui ʻana o ka cell, a me ka hoʻoponopono ʻana i nā kiko. No laila, hiki ke hoʻohana ʻia ʻo Ipamorelin e mālama i ka hemahema o ka hormone ulu a i ʻole nā maʻi ʻē aʻe e pili ana i ka lawa ʻole o ka hormone ulu [7].
2. Hoʻomaikaʻi i ka hana o ka ʻōpū
ʻO ka hoʻomaʻemaʻe ʻana i ka ʻōpū:
Ma nā hiʻohiʻona rodent, hoʻolalelale ʻo Ipamorelin i ka hoʻokaʻawale ʻana o ka ʻōpū i nā hiʻohiʻona o ka hale o ka postoperative ma o kahi mīkini i hoʻopili ʻia e ka hoʻoulu ʻana o ka hormone ulu e hoʻokuʻu ana i ka peptide receptor, e pili ana i nā neurons cholinergic excitatory [1] . ʻO ka ʻoki ʻana i ka ʻōpū ke alakaʻi i ka hoʻokaʻawale ʻana o ka ʻōpū, a hiki i ka lawelawe ʻana iā Ipamorelin ke hoʻemi nui i ka nui o nā meaʻai i koe i loko o ka ʻōpū, a laila e hoʻomaikaʻi ai i ka motility ʻōpū.
Hoʻonui i ka peristalsis gastrointestinal:
I loko o nā ʻano rodent o postoperative ileus, hiki iā Ipamorelin ke hoʻomaikaʻi i nā hōʻailona o nā maʻi. No ka laʻana, i loko o kahi kiʻi ʻiole, hiki i ka Ipamorelin ke hoʻemi i ka manawa i ka defecation mua ma hope o ke kaʻina hana, hoʻonui i ka puka fecal, ka ʻai ʻana i ka meaʻai, a me ke kaumaha [4] . Hiki i ka hoʻohana hou ʻana o Ipamorelin ke hoʻonui nui i ka hoʻoulu ʻana o ka fecal cumulative, ka lawe ʻana i ka meaʻai, a me ka loaʻa ʻana o ke kaumaha, e hōʻike ana i kona hopena hoʻoponopono maikaʻi i ka hana o ka ʻōpū.
3. Hoʻomaha i ka ʻeha
Hoʻopau i ka ʻeha visceral a me ka somatic:
Hōʻike ka noiʻi ʻo Ipamorelin, he hormone ulu e hoʻokuʻu ana i ka agonist receptor peptide, he mau waiwai antinociceptive. I nā hiʻohiʻona hoʻokolohua me ka ʻole o ka mumū epithelial colonic, hiki i ka Ipamorelin ke hōʻemi nui i ka hypersensitivity visceral non-inflammatory a me somatic mechanical allodynia [6].
Hiki ke hoʻopili ʻia kāna ʻano hana e ka hormone ulu e hoʻokuʻu ana i ka peptide receptor, e komo ana i ka hoʻoponopono ʻana i ka hypersensitivity visceral a me ka somatic, e hāʻawi ana i kahi ala hou no ka mālama ʻana i ka ʻeha visceral a me ka somatic.
He aha ka holomua noiʻi o Ipamorelin i ka mālama ʻana i ka hemahema o ka hormone ulu?
ʻO ka hemahema o ka hormone ulu kahi maʻi i hoʻokumu ʻia e ka lawa ʻole o ka huna ʻana o ka hormone ulu mai ka pituitary gland anterior, hiki ke hoʻopilikia i ka ulu a me ka ulu ʻana o nā keiki a me ke kino o ke kino o nā pākeke. I nā makahiki i hala iho nei, ʻo Ipamorelin, ma ke ʻano he secretagogue hormone ulu, ua huki nui i ka nānā ʻana i ka mālama ʻana i ka hemahema o ka hormone ulu. ʻO kēia ka holomua noiʻi kūpono o Ipamorelin i ka mālama ʻana i ka hemahema o ka hormone ulu.
1. ʻO ka hopena hoʻoulu o Ipamorelin i ka uluʻana o ka hormone ulu
Hiki i ka Ipamorelin ke hoʻoulu i ka huna o ka hormone ulu. Hōʻike nā noiʻi hiki iā Ipamorelin ke hana synergistically me ka hormone hoʻokuʻu i ka hormone ulu (GHRH) e hoʻonui i ka hoʻokuʻu ʻana o ka hormone ulu [8] . Ma nā hoʻokolohua holoholona, ma hope o 21 mau lā o ka mālama mau ʻana me Ipamorelin i nā ʻiole wahine ʻōpio, ke hoʻohālikelike ʻia me ka pūʻulu mana, ua hoʻonui ʻia ka hoʻokuʻu ʻana o ka hormone ulu basal i ka moʻomeheu monolayer o nā pūnana pituitary. I ka manawa like, hiki iā Ipamorelin a me GHRH ke hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu mai nā cell pituitary moʻomeheu in vitro. Eia naʻe, i ka hui pretreatment GHRH, ʻaʻole i hoʻonui ʻia ka pane ʻana o ka hormone ulu i ka hoʻoulu ʻana, ʻoiai i ka hui pretreatment Ipamorelin, ʻaʻohe ʻano desensitization like, e hōʻike ana ʻaʻole i alakaʻi ʻo Ipamorelin i ka desensitization o ka pane hormone ulu i nā ʻiole wahine ʻōpio [8].
2. ʻO ka hopena o Ipamorelin ma ke kaumaha
Hiki ke hoʻonui maikaʻi i ke kaumaha o nā ʻiole wahine ʻōpio ʻo Ipamorelin. Hōʻike ka nānā ʻana i kēlā me kēia lā i ka pakeneka o ka loaʻa ʻana o ke kaumaha ma ka hui hoʻomaʻamaʻa Ipamorelin a me ka hui pretreatment GHRH ʻoi aku ka kiʻekiʻe ma mua o ka pūʻulu mana [8] . Hoʻopili kēia i ka ʻoiaʻiʻo ʻo Ipamorelin e hoʻoulu i ka huna ʻana o ka hormone ulu, ʻo ia ka mea e hoʻoikaika ai i ka synthesis protein a me ka ulu ʻana o ka cell.
3. ʻO ka hopena o Ipamorelin i ka hana iwi
I loko o kahi ʻano ʻiole makua, ua ʻike ʻia e hiki i ka ulu ulu ʻana o ka hormone secretagogue Ipamorelin ke pale aku i nā hopena catabolic o nā glucocorticoids (GC) ma luna o ka ʻiʻo iwi a me ka iwi. Ke hoʻohālikelikeʻia me ka hui i hoʻopiliʻia me GC wale nō, i nā holoholona i hoʻokomoʻia me GC a me Ipamorelin, ua piʻi nui ka tetanic tetanic o kaʻiʻo bipi, a ua piʻi ka nui o ka iwi periosteal iʻehā manawa [8, 9] . Hōʻike kēia i ka hopena maikaʻi o Ipamorelin i ka mālama ʻana i ka ikaika o ka ʻiʻo a me ka hoʻoikaika ʻana i ka hoʻokumu ʻana o ka iwi, a hiki ke kōkua i ka pale ʻana i nā pilikia e like me ka osteoporosis i nā maʻi me ka hemahema o ka hormone ulu.
4. ʻO ka hopena o Ipamorelin i ka hana gastrointestinal
Ma ke ʻano he agonist hormone e hoʻokuʻu ana i ka hormone ulu a me ka ulu ʻana o ka hormone-hoʻokuʻu i ka peptide receptor agonist, ua hōʻike ʻo Ipamorelin i ka maikaʻi therapeutic i loko o ke ʻano ʻiole o ka maʻi maʻi ʻōpū postoperative. ʻO ka hoʻokele hoʻokahi o Ipamorelin a i ʻole ka ulu ʻana o ka hormone-releasing peptide (GHRP) -6 i hoʻopōkole i ka manawa i ka neʻe ʻana o ka ʻōpū ma hope o ka hana mua, akā ʻaʻohe hopena i ka cumulative fecal output, intake meaʻai, a i ʻole ke kaumaha. Hoʻonui ʻo Ipamorelin i ka puka fecal cumulative, ka ʻai ʻana i ka meaʻai, a me ka loaʻa ʻana o ke kaumaha. Hōʻike kēia he kuleana ko Ipamorelin i ka hoʻomaikaʻi ʻana i ka hana gastrointestinal a hiki ke kōkua i ka hoʻomaikaʻi ʻana i ka hana digestive a absorptive i nā poʻe maʻi me ka hemahema o ka hormone ulu. [4].
I ka hōʻuluʻuluʻana, ma keʻano he mea hoʻolaha hoʻopalekana hormone ulu, ua hoʻoikaika maikaʻiʻo Ipamorelin i ka hoʻokuʻuʻana i ka hormone ulu ma o ka hoʻouluʻana i ka hormone ulu-hoʻokuʻu peptide receptor (GHS receptor), me kaʻole e hoʻololi nui i nā kiʻekiʻe o ka hormone adrenocorticotropic (ACTH) a me ka cortisol. ʻO kāna mau hana e hoʻoikaika i ka ulu ʻana o ka hormone huna, hoʻoponopono i ka motility gastrointestinal, a me ka hoʻēmi ʻana i ka ʻeha. ʻO kāna koho kiʻekiʻe a me nā hiʻohiʻona multi-target e hāʻawi i ka hiki ke hoʻohana i ka lāʻau lapaʻau, e kūpono ia no ka hoʻohana ʻana i nā kūlana e like me ka ulu ʻana o ka hormone deficiency, postoperative intestinal obstruction, a me ka mālama ʻana i ka ʻeha.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He mea noiʻi ʻo Raun K me ke Kulanui ʻenehana o Denmark (DTU) a me ka Novo Nordisk Foundation. ʻO kāna mau noiʻi noiʻi e pili ana i nā ʻano aʻoaʻo he nui, e komo pū me Endocrinology & Metabolism, Orthopedics, Nutrition & Dietetics, Veterinary Science, a me ʻEngineering. Hoʻokumu pinepine kāna hana i ka hoʻomohala ʻana i nā hoʻonā hoʻomau a me nā mea hou, ʻo ia hoʻi i ka pōʻaiapili o ka biotechnology a me nā ʻoihana bio-based.
Ua kōkua ʻo Raun K i nā papahana e pili ana i ka Novo Nordisk Foundation Center for Biosustainability ma DTU, i hoʻolaʻa ʻia no ka holomua ʻana i ka hoʻolālā ʻana o ka hale hana cell, metabolic engineering, a me ka biology synthetic no ka bioproduction hoʻomau. Eia kekahi, ua komo ʻo ia i nā hana noiʻi e hoʻemi ana i ka hilinaʻi ʻana i nā mea i hoʻokumu ʻia i ka mōʻalihaku a me ka hoʻolaha ʻana i nā hoʻololi ʻōmaʻomaʻo ma o nā hopena bioproduction.
Hoʻopili pū kāna hana i nā noi ʻenekinia, e like me ka hoʻomohala ʻana i nā catalysts a me nā bioprocesses no ka hoʻomau ʻana i ka ʻoihana a me ke kaiapuni. Hoʻopili ʻo Raun K i nā noiʻi ʻepekema a me nā noi kūpono, e hāʻawi nui ana i nā ʻāpana kula a me nā ʻoihana. Ua helu ʻia ʻo Raun K ma ka ʻōlelo kuhikuhi [3].
▎ Nā ʻōlelo pili
[1] ʻO Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. ʻO ka maikaʻi o ipamorelin, kahi mimetic ghrelin, ma ka dysmotility o ka ʻōpū i loko o kahi ʻano rodent o postoperative ileus. Nūpepa o ka pharmacology hoʻokolohua 2012; 4: 149-55.DOI:10.2147/JEP.S35396.
[2] Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection maʻi. INT J COLORECTAL DIS 2014; 29(12): 1527-34.DOI:10.1007/s00384-014-2030-8.
[3] Raun K, Hansen BS, Johansen NL, et al. ʻO Ipamorelin, ka mea huna mua o ka hormone ulu. EUR J ENDOCRINOL 1998; 139(5): 552-61.DOI:10.1530/eje.0.1390552.
[4] Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, ma kahi Rodent Model of Postoperative Ileus. J PHARMACOL EXP THER 2009; 329(3): 1110-6.DOI:10.1124/jpet.108.149211.
[5] Adeghate EA, Ponery AS. Mechanism o ipamorelin-evoked insulin hoʻokuʻu mai ka pancreas o nā ʻiole maʻamau a me ka maʻi diabetes. Nā leka neuro endocrinology 2004; 25 6: 403-6.
[6] N Mohammadi E, Louwies T, Pietra C, Northrup SR, Greenwood-Van Meerveld B. Attenuation of Visceral and Somatic Nociception e Ghrelin Mimetics. J Exp Pharmacol 2020; 12: 267-74.DOI:10.2147/JEP.S249747.
[7] Papak M. Ipamorelin - struktura i funkcija.; 2016.
https://www.semanticscholar.org/paper/IpamorelinstrukturaifunkcijaPapak/6f1496dcedd60ec60a90be4c1f317a8bad7efb08
[8] Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. ʻO ka hopena o ka hoʻomaʻamaʻa mau ʻana me ka ulu ʻana o ka hormone secretagogue Ipamorelin, i nā ʻiole wahine ʻōpio:: pane somatotroph in vitro. HISTOL HISTOPATHOL 2002; 17(3): 707-14. DOI: 10.14670/HH-17.707
[9] Andersen NB, F KMO, Johansen PB, Andreassen TT, Rtoft GO, Oxlund H. ʻO ka ulu ʻana o ka hormone secretagogue ipamorelin e kūʻē i ka emi ʻana o ka glucocorticoid-induced i ka hoʻokumu ʻana o ka iwi o nā ʻiole makua. Noiʻi ʻo Growth Hormone & IGF : puke pai o ka Growth Hormone Research Society a me ka International IGF Research Society 2001; 11 5: 266-72.DOI:10.1054/GHIR.2001.0239.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.